Mumps

Overview
Epidemiology
Pathophysiology
Etiology and Risk Factors
Clinical Presentation
Diagnosis
Treatment
Complications
Prognosis
Prevention
Recent Research and Advances
Research Papers
Connections
Featured Videos

1. Overview

Mumps is a contagious viral infection caused by the mumps virus, a member of the Paramyxoviridae family (genus Rubulavirus). The name most people associate with the disease is the swollen jaw — the puffy, chipmunk-like swelling below and in front of the ears that was once a common sight in schoolchildren before vaccination became routine. That swelling comes from inflammation of the parotid glands, the largest of the three pairs of saliva-producing glands in the face, and it is the disease’s signature sign.

For most people, mumps is an unpleasant but self-limited illness lasting a week or two: fever, headache, a general feeling of being run-down, and then the swollen glands. But mumps is not merely a cosmetic nuisance. It can cause a range of serious complications, particularly in people who have passed puberty, and understanding those complications — above all the risk of testicular involvement in males — is what makes mumps worth taking seriously even in the vaccine era. It also retains relevance today because, despite high vaccination rates, mumps continues to cause outbreaks in colleges and communities, driven by waning immunity in young adults.

Before the introduction of the measles-mumps-rubella (MMR) vaccine in 1967, mumps was an almost universal childhood experience in the United States, with roughly 150,000 reported cases per year — and far more unreported ones. Mumps was also, notably, the most common cause of viral meningitis and acquired sensorineural hearing loss in children in the pre-vaccine era. Vaccination transformed that picture: cases dropped by more than 99%. Yet the virus has never been eradicated, and the 21st century has seen repeated reminders — including large outbreaks at universities — that mumps remains an active concern for unvaccinated and under-protected individuals.

2. Epidemiology

Mumps circulates worldwide and, before routine immunization, displayed a characteristic seasonal pattern: cases peaked in late winter and spring, with epidemic cycles every few years. The virus spreads easily wherever people live in close quarters — schools, dormitories, military barracks, sports teams. Historically, most infection happened in childhood, conferring lifelong natural immunity; this meant that adults were relatively protected by prior exposure. Vaccination changed the epidemiological landscape profoundly, largely eliminating childhood disease — but also creating a new pattern in which young adults have become the primary group affected in contemporary outbreaks.

The shift toward older age groups in current outbreaks reflects two realities. First, routine childhood vaccination prevents disease in children, so the pool of susceptibles shifts upward in age. Second, vaccine-induced immunity wanes over time, meaning that people vaccinated in childhood may have declining protection by their late teens and twenties — precisely when they enter densely populated college environments. This dynamic drove the well-publicized 2016 outbreaks at Harvard University and other US colleges, where hundreds of vaccinated students developed mumps. The Advisory Committee on Immunization Practices (ACIP) responded in 2018 by recommending a third MMR dose for people at increased risk during active outbreaks.

In the pre-vaccine era, mumps infection before puberty was the norm, and the feared complications of orchitis and oophoritis (which require hormonal maturity) were therefore uncommon in those cases. The post-vaccine shift toward adult cases has paradoxically increased the proportion of cases complicated by these gonadal conditions, because more cases now occur in sexually mature individuals. Globally, in regions without universal vaccination, mumps remains endemic with substantial ongoing morbidity.

3. Pathophysiology

Mumps virus enters the body through the respiratory tract — inhaled in droplets or taken in via contaminated saliva — and first replicates in the epithelial cells lining the upper airway and in local lymph nodes. From there it spreads through the bloodstream (viremia) to various organs, with a particular affinity for glandular and neural tissues. This hematogenous spread explains why mumps can affect so many different organs: the parotid glands, the testes, the ovaries, the pancreas, the meninges, and the inner ear can all be seeded by the circulating virus.

The parotitis that defines the clinical picture results from the virus infecting the ductal epithelium of the parotid gland, triggering intense local inflammation. The gland swells, becomes tender, and the edema pushes the ear lobe upward and outward — the classic visual sign. The inflammatory process is driven primarily by the immune response, not direct tissue destruction by the virus alone, which is why the swelling typically resolves within a week to ten days as immunity clears the infection.

In the testes, mumps virus infects Sertoli cells and Leydig cells, triggering inflammation within the tightly enclosed fibrous tunica albuginea. Because this tough sheath cannot expand, inflammatory pressure builds against the tissue inside, causing the intense pain of orchitis and the potential for ischemic injury to the tubules that produce sperm. The degree of lasting damage — tubular atrophy and reduced sperm production — depends on the severity and duration of this pressure-related injury. In the inner ear, mumps can trigger an acute inflammatory or ischemic event affecting the cochlea or its blood supply, causing sudden, permanent unilateral deafness.

The incubation period from exposure to first symptoms is typically 16–18 days, with a range of 12–25 days. A person with mumps is contagious from about 2 days before parotid swelling appears to 5 days after it begins — meaning that infected individuals are spreading the virus before they even know they are sick, a feature that makes containment difficult once an outbreak is underway.

4. Etiology and Risk Factors

The single cause of mumps is the mumps virus (genus Rubulavirus, family Paramyxoviridae). It is a single-stranded, negative-sense RNA virus with a lipid envelope. The envelope carries surface proteins — hemagglutinin-neuraminidase (HN) and fusion protein (F) — that enable the virus to attach to and enter host cells. Only one serotype is known, which is the basis for the effectiveness of a single vaccine strain, although multiple genotypes circulate globally (genotype G predominating in recent US outbreaks).

Mumps spreads via respiratory droplets and saliva, through direct contact with an infected person’s secretions, or via contaminated surfaces. Close-contact settings — households, classrooms, dormitories, sports teams — are the highest-risk environments. People at greatest risk of infection or serious complications include:

Unvaccinated individuals of any age — the single largest modifiable risk factor.
Young adults in dense-living settings (college dormitories, military camps, sports training environments) where close contact sustains transmission.
People vaccinated more than a decade ago, whose immunity may have waned below fully protective levels, even if two doses were received on schedule.
Post-pubertal males, who face heightened risk of orchitis if infected.
International travelers visiting or returning from regions with ongoing mumps circulation and lower vaccination coverage.
Anyone with a compromised immune system, who may have a more severe or prolonged course.

5. Clinical Presentation

The clinical picture of mumps has two phases: a short, flu-like prodrome followed by the characteristic glandular swelling. Roughly 20–30% of mumps infections produce no symptoms at all (subclinical infection) — yet these individuals are still contagious and can spread the virus to others.

Prodrome: the early warning (1–3 days before swelling)

Most symptomatic cases begin with a prodrome of fever (typically 38–39°C / 100–102°F), headache, malaise, myalgia (muscle aches), and anorexia. At this stage the illness looks like any generic viral infection — nothing points specifically to mumps. The prodrome lasts 1–3 days before the defining sign appears.

Parotitis: the classic sign

The swelling of one or both parotid glands is the hallmark of mumps. The parotid glands sit just below and in front of each ear, and when they swell they push the earlobe upward and outward and create the characteristic puffy, tender jaw most people associate with the disease. In about 75% of symptomatic cases both sides eventually swell (bilateral parotitis); in the remaining 25% only one side is affected (unilateral parotitis). Swelling is typically maximal within 1–3 days and resolves over about a week. The swollen gland is tender to the touch, and opening the mouth or chewing — particularly anything acidic like orange juice or vinegar — is often sharply painful.

Other salivary glands can be affected too. The submandibular and sublingual glands (under the jaw and floor of the mouth) may swell in some cases, either alone or alongside parotid involvement. Pre-sternal edema — soft swelling over the breastbone — is an unusual but recognized finding that reflects lymphatic spread of the inflammation.

Recognizing atypical presentations

Not every case looks textbook. In vaccinated individuals, illness may be milder and parotid swelling less pronounced or even absent. In adults, especially males, the first symptom prompting medical attention may be testicular pain from orchitis appearing before — or even without — obvious parotid swelling. Mumps does not always announce itself with the classic “hamster cheeks” appearance, particularly in the setting of partial vaccine-induced immunity.

6. Diagnosis

Diagnosis of mumps is part clinical recognition and part laboratory confirmation. The clinical picture of parotitis with fever and constitutional symptoms during an exposure period is strongly suggestive, but laboratory testing is important for public health surveillance, outbreak control, and distinguishing mumps from other causes of parotid swelling (bacterial parotitis, parotid stones, drug reactions, other viral infections including parainfluenza and EBV).

Laboratory tests

RT-PCR (reverse transcription polymerase chain reaction) is the preferred confirmatory test during the first few days of illness. Specimens are collected from a buccal swab (swabbed inside the cheek near the parotid duct opening, ideally while massaging the gland) or from urine. PCR sensitivity is highest in the first three days of parotid swelling and declines sharply after that. Both buccal swab and urine should be collected for highest yield.
Mumps IgM serology can be positive early but is unreliable in vaccinated individuals — up to 50% of vaccinated people with confirmed mumps may have a negative IgM result. Do not rule out mumps on the basis of a negative IgM in a vaccinated person.
Paired IgG serology (acute and convalescent samples 2–3 weeks apart showing a 4-fold rise in antibody titer) is more reliable in vaccinated individuals and is useful when PCR has been missed or is negative.
Virus culture from buccal swab or urine is definitive but slow (days to weeks); it serves primarily for genotyping during outbreak investigations rather than routine clinical diagnosis.

Practical considerations

For public health purposes, a case can be classified as probable on clinical grounds (parotitis for ≥2 days without another identified cause, with an epidemiological link to a confirmed case) or confirmed by laboratory testing. During an active outbreak, the clinical diagnosis is often sufficient to trigger isolation and contact tracing without waiting for laboratory results. Clinicians should report all suspected cases to their local health department, as mumps is a nationally notifiable disease in the United States.

7. Treatment

There is currently no specific antiviral treatment for mumps. Management is entirely supportive, aimed at relieving symptoms and preventing complications while the immune system clears the virus. The honest framing for patients: you will feel significantly better within a week to ten days for uncomplicated parotitis, but there is no medication that shortens the viral illness itself.

General supportive measures

Analgesics and antipyretics: Ibuprofen or other NSAIDs are helpful for pain and fever. Acetaminophen (paracetamol) is a good alternative, particularly in anyone where NSAIDs are contraindicated. Aspirin should be avoided in children due to the risk of Reye syndrome.
Hydration: Drink plenty of fluids. Because chewing and swallowing acidic or spicy foods can be painful, soft, bland foods are more comfortable during the acute phase of parotitis. Warm soups, broths, yogurt, and mashed foods work well. Avoid citrus juices and vinegar-containing foods, which stimulate saliva flow and worsen parotid pain.
Warm or cool compresses applied gently to the swollen glands can ease discomfort and are safe to use as needed.
Rest is important, particularly in the first several days when fever and malaise are prominent.

Management of orchitis

For post-pubertal males who develop orchitis, supportive care is the mainstay:

Bed rest during the acute painful phase.
Scrotal support: Wearing snug-fitting supportive underwear or using a rolled towel under the scrotum while in bed reduces the pulling sensation from the weight of the inflamed testes and provides significant comfort.
Ice packs applied intermittently to the scrotum can reduce inflammation and pain.
NSAIDs are the analgesic of choice, both for pain relief and for their anti-inflammatory effect.
Corticosteroids have been studied in mumps orchitis but have not been shown to prevent testicular atrophy; they are not routinely recommended.

Isolation to prevent spread

People with mumps should be isolated for 5 days from the onset of parotid swelling to prevent spreading the virus. This means staying home from school, work, and public gatherings. Household contacts who are unvaccinated or under-vaccinated should be vaccinated as soon as possible; post-exposure vaccination cannot reliably prevent disease in someone already incubating the virus, but its main value is protecting against future exposures.

8. Complications

Mumps can cause a range of serious complications beyond parotitis. Complications are generally more common and more severe in post-pubertal individuals.

Orchitis

Orchitis is the most feared complication in males. It occurs in 20–38% of post-pubertal males with symptomatic mumps. It is typically unilateral (one testicle) in about 85% of cases and usually develops approximately one week after the onset of parotitis, though it can occasionally appear before or without parotid swelling. Onset is often sudden: severe testicular pain and swelling, usually accompanied by fever, nausea, and headache. The acute phase lasts about 4–7 days. Some degree of testicular atrophy occurs in approximately 50% of affected testes. Despite the alarming rate of atrophy, bilateral orchitis causing complete sterility is rare (estimated <1% of mumps orchitis cases), because both testes are involved simultaneously in only about 15% of orchitis cases, and even atrophy does not always abolish sperm production from the remaining tissue.

Oophoritis

Oophoritis (ovarian inflammation) occurs in roughly 5% of post-pubertal females with mumps. Symptoms include lower abdominal pain and tenderness, mimicking appendicitis or ovarian cyst complications. Oophoritis is generally mild and self-limiting. Fertility is not significantly affected in most cases, though premature ovarian insufficiency has been reported as a rare sequela.

Aseptic meningitis

Aseptic (viral) meningitis occurs in approximately 10% of mumps cases, making mumps one of the historically important causes of viral meningitis. Cerebrospinal fluid (CSF) shows a typical viral pattern: lymphocytic pleocytosis, normal glucose, and mildly elevated protein. Symptoms include headache, neck stiffness, and photophobia. Mumps meningitis is almost always self-limiting and resolves without specific treatment over 3–10 days. Meningitis can occur in people who have mild or absent parotitis, so the absence of swollen glands does not exclude mumps.

Encephalitis

True encephalitis is rare, occurring in fewer than 2 per 10,000 cases. It is more serious than aseptic meningitis: symptoms include altered consciousness, seizures, and focal neurological deficits. Persistent neurological sequelae are possible in severe cases.

Sensorineural hearing loss

Sudden unilateral sensorineural hearing loss is a serious but rare complication, estimated at approximately 1 in 20,000 cases. It typically affects one ear, appears suddenly, and is permanent. In the pre-vaccine era, mumps was the leading infectious cause of acquired unilateral deafness in children. This complication has become very rare since MMR vaccination became routine, but it represents a compelling reason to vaccinate even when mumps is perceived as mild.

Pancreatitis

Pancreatitis occurs in approximately 4% of mumps cases, with nausea, vomiting, and upper abdominal pain. Laboratory testing shows elevated serum amylase and lipase. The vast majority of cases are mild and self-limiting, resolving over a few days with rest and hydration.

Other complications

Less common complications include myocarditis (usually mild and subclinical), arthritis, thyroiditis, nephritis, and thrombocytopenic purpura. Mumps infection during the first trimester of pregnancy has been associated with an increased risk of spontaneous abortion.

9. Prognosis

For most people, mumps is a fully recoverable illness. Uncomplicated parotitis resolves within 7–10 days and leaves no lasting effects. The infection confers lifelong natural immunity in virtually all cases.

The prognosis is less uniformly benign when complications occur. Orchitis, while rarely causing complete sterility, may leave one or both testes somewhat smaller than before, and some studies have found modestly reduced sperm counts in affected men — though fertility is usually preserved. Men with bilateral orchitis are at somewhat higher risk of fertility impairment, but absolute infertility remains uncommon.

Aseptic meningitis from mumps carries an excellent prognosis, with full recovery the rule. Encephalitis is the most serious neurological complication and can cause lasting deficits in a minority of those affected. Sensorineural hearing loss, when it occurs, is typically permanent and does not improve with time, making prevention through vaccination the only reliable strategy against it. Overall, the modern burden of severe mumps outcomes is concentrated in unvaccinated and under-vaccinated individuals.

10. Prevention

Vaccination is overwhelmingly the most effective strategy for preventing mumps. The MMR vaccine, introduced in the United States in 1967, reduced annual mumps cases by over 99% from the pre-vaccine era baseline.

MMR vaccine: two-dose schedule

The standard childhood immunization schedule calls for two doses of MMR vaccine. The first dose is given at 12–15 months of age; the second dose is given at 4–6 years (kindergarten entry). Two doses of MMR vaccine are 88–95% effective at preventing mumps — highly effective, though not perfect. This residual gap, combined with waning immunity over time in young adults, accounts for the continued occurrence of outbreaks in vaccinated populations.

Adults born before 1957 are generally considered immune by presumption, as nearly all were infected before vaccination was available. Adults born in 1957 or later who have no documentation of prior vaccination or serologic immunity should receive at least one dose of MMR; those in high-risk settings (healthcare workers, international travelers, college students) should have two documented doses.

Third MMR dose in outbreak settings

In response to the 2016 and subsequent college outbreaks, the ACIP in 2018 recommended a third dose of MMR for people at increased risk during a mumps outbreak — principally those in close-contact settings who have already received two doses and are directly affected by the outbreak. The third dose provides a short-term boost in immunity and has been shown to reduce the risk of mumps in the targeted group during active outbreaks.

Practical prevention behaviors

During an active outbreak or when caring for someone with mumps:

Hand washing with soap and water frequently, especially after contact with a sick person’s secretions or surfaces.
Avoid sharing cups, utensils, lip balm, or anything that has been in contact with someone’s mouth.
People with mumps should cover coughs and sneezes and be isolated from susceptible household members for 5 days from the onset of parotid swelling.
In outbreak settings, promptly report symptoms to campus health services so that exposed contacts can be identified and protected.

MMR vaccine safety

The MMR vaccine has been studied in tens of millions of people over more than five decades. The extensive body of evidence shows it is safe and does not cause autism — a claim that originated from a since-retracted fraudulent 1998 paper. Serious adverse reactions are genuinely rare; minor reactions (sore arm, low-grade fever, faint transient rash a week or two after the first dose) are common but harmless. The vaccine is contraindicated in people who are severely immunocompromised, allergic to any component, or pregnant (it contains live attenuated virus).

11. Recent Research and Advances

Mumps research in recent years has been driven by a puzzle that practicing physicians encounter regularly: why do two-dose vaccinated people still get mumps? Unraveling that question has shed light on both the biology of the virus and the limits of current vaccines.

The leading explanation for breakthrough infections in vaccinated individuals is waning immunity. Cohort studies following vaccinated populations over time have shown that protective antibody levels decline measurably over years to decades. By the time a two-dose vaccinee reaches their early twenties — having received their doses at ages one and five — immunity may have fallen below fully protective thresholds in a significant proportion of individuals.

The 2016 college outbreaks provided an opportunity to characterize genotype G mumps strains circulating in the United States and to compare them with the Jeryl Lynn vaccine strain (genotype A) used in MMR. While antigenic differences exist, most evidence suggests that cross-protection is substantial and that waning immunity, rather than immune evasion by the virus, is the primary driver of breakthrough cases. However, questions remain and ongoing surveillance continues to track whether virus evolution is playing a contributing role.

Research into the third MMR dose recommendation has confirmed short-term benefit in outbreak settings but highlighted the need for longer-term follow-up data. Some immunologists have proposed that next-generation mumps vaccines designed with stronger or longer-lasting immunogens — possibly using different adjuvants or alternative antigen targets — could provide more durable protection. Trials of such candidates are in early stages.

For mumps orchitis, a small number of studies have investigated whether early antiviral or anti-inflammatory therapy can reduce the risk of testicular atrophy. Results have been mixed and unconvincing, and no antiviral has entered routine clinical practice for this indication. The most definitive protection against orchitis remains what it has always been: preventing mumps infection in the first place through vaccination.

12. References & Research

Historical Background

Mumps was well-recognized as a distinct clinical entity for centuries before its viral cause was identified. The disease was described by Hippocrates in the fifth century BC, who noted the characteristic parotid swelling and the association with testicular involvement in young men. The viral etiology was established in 1934 when Johnson and Goodpasture demonstrated transmission to monkeys using filtered (cell-free) parotid gland secretions — proof that a filterable virus, not a bacterium, was responsible. Cultivation of the mumps virus in embryonated eggs in the 1940s opened the door to vaccine development. The first effective mumps vaccine, using the live attenuated Jeryl Lynn strain (named after the developer’s daughter, from whose throat the original virus was isolated in 1963), was developed by Maurice Hilleman at Merck and licensed in the United States in 1967. Combined into the MMR vaccine alongside measles and rubella vaccines, it became one of the most successful public health interventions in history, reducing mumps incidence by more than 99% in vaccinated populations. The 21st century added a new chapter: the recognition that waning immunity in young adults and the persistence of unvaccinated pockets can sustain outbreaks even in high-coverage populations, prompting the ACIP’s 2018 third-dose recommendation for people at heightened risk during active outbreaks.

Key Research Papers

Hviid A, Rubin S, Mühlemann K. Mumps. Lancet. 2008;371(9616):932–944. doi:10.1016/S0140-6736(08)60419-5. PMID: 18342688.
Dayan GH, Quinlisk MP, Parker AA, et al. Recent resurgence of mumps in the United States. New England Journal of Medicine. 2008;358(15):1580–1589. doi:10.1056/NEJMoa0706589. PMID: 18403766.
Abubakar I, Irvine L, Aldus CF, et al. A systematic review of the epidemiology of mumps. Tropical Medicine & International Health. 2012;17(10):1166–1177. doi:10.1111/j.1365-3156.2012.03060.x. PMID: 22831915.
Masarani M, Wazait H, Dinneen M. Mumps orchitis. Journal of the Royal Society of Medicine. 2006;99(11):573–575. doi:10.1177/014107680609901116. PMID: 17082302.
Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bulletin of the World Health Organization. 1999;77(1):3–14. PMID: 10063655. PubMed.
Marin M, Marlow M, Moore KL, Patel M. Recommendation of the Advisory Committee on Immunization Practices for use of a third dose of mumps virus–containing vaccine in persons at increased risk during a mumps outbreak. MMWR Morbidity and Mortality Weekly Report. 2018;67(1):33–38. doi:10.15585/mmwr.mm6701a7. PMID: 29324729.
Wharton M, Cochi SL, Hutcheson RH, Bistowish JM, Schaffner W. A large outbreak of mumps in the postvaccine era. Journal of Infectious Diseases. 1988;158(6):1253–1260. doi:10.1093/infdis/158.6.1253. PMID: 3198947.
Shanley JD. The resurgence of mumps in young adults and adolescents. Cleveland Clinic Journal of Medicine. 2007;74(1):42–48. doi:10.3949/ccjm.74.1.42. PMID: 17249513.
Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clinical Infectious Diseases. 2008;47(3):401–409. doi:10.1086/589862. PMID: 18558875.
Rubin SA, Sauder C, Carbone KM. Mumps virus. In: Fields Virology, 6th ed. PubMed search: mumps virus pathogenesis Rubulavirus.
MMR vaccine efficacy and immunogenicity. PubMed search: mumps MMR vaccine efficacy.
Mumps orchitis and male fertility outcomes. PubMed search: mumps orchitis male fertility outcomes.

Research Papers

The following PubMed searches link directly to current, peer-reviewed literature on mumps. Each opens a live PubMed query in a new tab so you can explore the most recent studies on a given aspect of the disease.

Connections

Back to Table of Contents